News

Second Genome Presents New Preclinical Data at AACR 2022 Demonstrating that SG-3-06686, a CXCR3 Chemokine Receptor Modulator, Induces Migration of Immune Effector Cells, Inhibits Tumor Growth as Monotherapy and Boosts Anti-Programmed Death Protein-1 (PD-1) Activity

April 8, 2022,

READ MORE

Second Genome Announces Bayer Exercised Option Following Completion of Multi-Year Collaboration

March 2, 2022,

READ MORE

Second Genome Virtual KOL Event Highlighted Critical Role of Mucosal Healing and PAI-1/2 in Inflammatory Bowel Disease (IBD)

February 24, 2022,

READ MORE

Second Genome Presents New Preclinical Data for SG-5-00455, Potential First-in-Class Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD), at the 17th Congress of European Crohn’s and Colitis Organization (ECCO)

February 18, 2022,

READ MORE

Second Genome to Host Virtual KOL Event to Discuss the Role of Mucosal Healing and PAI-1/2 in Inflammatory Bowel Disease on February 23

February 14, 2022,

READ MORE

Second Genome Nominates Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD)

February 10, 2022,

READ MORE

Second Genome Appoints Joseph Dal Porto, Ph.D., as Chief Scientific Officer

January 19, 2022,

READ MORE

Second Genome Granted U.S. Patent for Proteins for the Treatment or Prevention of Epithelial Barrier Function Disorders

December 20, 2021,

READ MORE

Second Genome Presents Preclinical Data at Crohn’s & Colitis Foundation’s® IBD Innovate Conference for Potential First in Class Mucosal Healing Therapeutic SG-5-00455

November 18, 2021,

READ MORE

Second Genome Presents Preclinical Data at SITC 2021 Demonstrating that a CXCR3-Positive Allosteric Modulator, SG-3-00802, Targets a Key Mechanism Required for Efficacious Immunotherapy

November 12, 2021,

READ MORE